Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) has jumped 247% in 2026 following positive Phase 3 trial data for avexitide, its experimental treatment for post-bariatric hypoglycemia. The condition, which affects patients after weight-loss surgery, currently has no FDA-approved therapies.

Analysts peg avexitide's peak sales potential at $1.5 billion if approved. The surge reflects investor enthusiasm for the first credible PBH treatment entering late-stage development. However, The Motley Fool warns much of the upside may already be reflected in the stock price after the triple-digit rally.

The publication suggests traders wait for a pullback to the $28-$30 per share range before establishing new positions. That would represent a meaningful retracement from current levels while preserving exposure to the regulatory pathway ahead.